[Cost-benefit analysis of the therapy of lipid metabolism disorders].
Karádi
I
I
D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy / Q000191:economics* / Q000628:therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*
D000960:Hypolipidemic Agents; D008055:Lipids
A zsíranyagcsere-zavarok kezelésének költség-hatás elemzéséhez.